Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22077069.
- Also identified by DOI 10.1164/rccm.201108-1536PP and PMC identifier 3297113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This perspective highlights advances in the understanding of the role of cellular metabolism in the pathogenesis of pulmonary hypertension. Insights gained in the past 20 years have revealed several similarities between the cellular processes underlying the pulmonary vascular remodeling in pulmonary hypertension and those seen in cancer processes. In line with these insights, there is increasing recognition that abnormal cellular metabolism, notably of aerobic glycolysis (the "Warburg effect"), the potential involvement of hypoxia-inducible factor in this process, and alterations in mitochondrial function, are key elements in the pathogenesis of this disease. The glycolytic shift may underlie the resistance to apoptosis and increased vascular cell proliferation, which are hallmarks of pulmonary hypertension. These investigations have led to novel approaches in the diagnosis and therapy of pulmonary hypertension.
Medical subject headings
- Energy Metabolism
- Hypertension, Pulmonary
- Hypoxia-Inducible Factor 1